The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Toni Choueiri
Leadership - ASCO
Stock and Other Ownership Interests - Abalytics Oncology; Bicycle Therapeutics; Curesponse; Faron Pharmaceuticals; Inndura; Osel; Pionyr; Precede Bio; Primium; Tempest Therapeutics
Honoraria - Alkermes; Analysis Group; Aravive; Arcus Biosciences; ASCO; AstraZeneca; Bayer; Bristol-Myers Squibb; Clinical Care Options; Eisai; EMD Serono; ESMO; Exelixis; Foundation Medicine; Gilead Sciences; Gilead Sciences; GlaxoSmithKline; Harborside Press; HiberCell; Infinity Pharmaceuticals; Ipsen; Janssen Oncology; Kanaph Therapeutics; Lancet Oncology; Lilly; MashupMD; Merck; Michael J. Hennessy Associates; Navinata Health; NCCN; NiKang Therapeutics; Novartis; Peloton Therapeutics; Pfizer; PlatformQ Health; Precede Bio; Prometheus; Roche/Genentech; Sanofi/Aventis; Scholar Rock; Tempest Therapeutics; The New England Journal of Medicine; UpToDate
Consulting or Advisory Role - alkermes; Analysis Group; Aravive; Arcus Biosciences; ASCO; AstraZeneca; Bayer; Bicycle Therapeutics; Bristol-Myers Squibb; Caris Life Sciences; Clinical Care Options; Curesponse; Eisai; EMD Serono; ESMO; Exelixis; Foundation Medicine; Gilead Sciences; Gilead Sciences; GlaxoSmithKline; Harborside Press; Infinity Pharmaceuticals; Ipsen; Janssen Oncology; Kanaph Therapeutics; Lancet Oncology; Lilly; Merck; Michael J. Hennessy Associates; Navinata Health; NCCN; Neomorph; NiKang Therapeutics; Novartis; Peloton Therapeutics; Pfizer; PlatformQ Health; Precede Bio; Prometheus; Roche/Genentech; Sanofi/Aventis; Scholar Rock; Tempest Therapeutics; The New England Journal of Medicine; UpToDate
Research Funding - Agensys (Inst); Arcus Biosciences (Inst); AstraZeneca (Inst); AVEO (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Eisai (Inst); Exelixis (Inst); GlaxoSmithKline (Inst); Ipsen (Inst); Merck (Inst); NiKang Therapeutics (Inst); Novartis (Inst); Peloton Therapeutics (Inst); Pfizer (Inst); Roche (Inst); Roche/Genentech (Inst); Seattle Genetics/Astellas (Inst); Takeda (Inst); TRACON Pharma (Inst)
Patents, Royalties, Other Intellectual Property - -International Patent Application No. PCT/US2018/058430, entitled “Biomarkers of Clinical Response and Benefit to Immune Checkpoint Inhibitor Therapy (Inst); ctDNA technologies; International Patent Application No. PCT/US2018/12209, entitled “PBRM1 Biomarkers Predictive of Anti-Immune Checkpoint Response (Inst)
Travel, Accommodations, Expenses - Alexion Pharmaceuticals; alligent; Analysis Group; AstraZeneca; Bayer; Bristol-Myers Squibb; Cerulean Pharma; Clinical Care Options; Corvus Pharmaceuticals; Eisai; EMD Serono; ESMO; Exelixis; Foundation Medicine; GlaxoSmithKline; Harborside Press; HERON; Ipsen; Kidney Cancer Association; Lancet Oncology; Lilly; Lpath; Merck; Michael J. Hennessy Associates; Navinata Health; NCCN; Novartis; Peloton Therapeutics; Pfizer; PlatformQ Health; Prometheus; Roche/Genentech; Sanofi/Aventis; The New England Journal of Medicine; UpToDate
Other Relationship - OTHER MEDICAL COMMUNICATION COMPANIES
(OPTIONAL) Uncompensated Relationships - AACR Scientific Advisory Council
 
Robert Motzer
Consulting or Advisory Role - Merck
Research Funding - Aveo (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Exelixis (Inst); Merck (Inst); Pfizer (Inst)
 
Jose Karam
Employment - MD Anderson Cancer Center; MD Anderson Physician’s Network
Stock and Other Ownership Interests - Medtek; ROM Tech
Honoraria - American Board of Urology; American Urological Association; ECRI; Medscape; Merck; Pfizer; Specialty Networks; Syapse; Telix Pharmaceuticals
Consulting or Advisory Role - American Board of Urology; American Urological Association; ECRI; Medscape; Merck; Pfizer; Specialty Networks; Syapse; Telix Pharmaceuticals
Research Funding - Elypta (Inst); Merck (Inst); Mirati Therapeutics (Inst); Roche/Genentech (Inst)
Travel, Accommodations, Expenses - American Board of Urology; American Urological Association
 
Dingwei Ye
No Relationships to Disclose
 
Zhisong He
Research Funding - MSD (Inst)
 
Christian Caglevic
Consulting or Advisory Role - Gilead Sciences
Research Funding - Abbvie (Inst); Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Athenex (Inst); Bayer HealthCare Pharmacuticals (Inst); Bicycle therapeutics (Inst); BioNTech SE (Inst); Bristol-Myers Squibb (Inst); Cogent Biosciences (Inst); daiichi Sankyo INC (Inst); Dizal Pharma (Inst); Exelixis (Inst); F. Hoffmann LaRoche (Inst); Geis-68 (Inst); Genmab (Inst); GlaxoSmithKline (Inst); Jazz Pharmaceuticals (Inst); Merck Sharp & Dohme (Inst); Merus; Merus (Inst); Novartis (Inst); Pfizer (Inst); PharmaMar (Inst); Roche (Inst); Sanofi (Inst); Taiho Oncology (Inst); Zymeworks (Inst)
 
Wesley Yip
Consulting or Advisory Role - Ferring; Gilead Sciences; SAI MedPartners; Telix Pharmaceuticals
Research Funding - Merck (Inst)
Travel, Accommodations, Expenses - Formedics
 
Cristina Suárez
Consulting or Advisory Role - Astellas Pharma; Bristol-Myers Squibb; Eisai; EUSA Pharma; Ipsen; Merck Sharp & Dohme; Pfizer; Roche/Genentech (Inst)
Speakers' Bureau - Bristol-Myers Squibb; Eisai; Ipsen; Merck Sharp & Dohme; Pfizer; Roche/Genentech
Research Funding - AB Science (Inst); Aragon Pharmaceuticals (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Exelixis (Inst); GlaxoSmithKline (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst); Sanofi Aventis GmbH (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Ipsen; Roche
 
Thomas Ferguson
Research Funding - AstraZeneca (Inst); Janssen (Inst); Lilly (Inst); MSD (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Bayer; Bayer
 
Wayne Yen Hwa Chang
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Eisai; Ipsen; Janssen; Merck; MSD; Pfizer
 
Carlos Rojas
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Knight Therapeutics/Biotoscana; Merck Sharp & Dohme; Pfizer; Roche
Research Funding - AstraZeneca; Bristol-Myers Squibb/Celgene; Knight Therapeutics/Biotoscana; Merck; Pfizer; Roche
Expert Testimony - AstraZeneca; Bristol-Myers Squibb; Roche
Travel, Accommodations, Expenses - Bristol-Myers Squibb
 
Roberto Iacovelli
Honoraria - Astellas Pharma; IPSEN; MSD; Pfizer
Consulting or Advisory Role - AAA/Endocyte/Novartis; Astellas Pharma; Bayer; Eisai; Genenta Science; Janssen; Merck; MSD; Novartis; Pfizer; Sanofi
Speakers' Bureau - Ipsen; Janssen; MSD; Pfizer; Sanofi
Research Funding - Bristol-Myers Squibb/Celgene (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Ipsen; Janssen; MSD; Pfizer
 
Yüksel Ürün
Honoraria - Abdi Ibrahim; Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Eczacibasi; Gen Ilaç; Gilead Sciences; Janssen; Merck Serono; MSD; Novartis; Pfizer; Roche
Consulting or Advisory Role - Abdi Ibrahim; Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Eczacibasi; Gen Ilaç; Gilead Sciences; Janssen; Merck Serono; MSD; Novartis; Pfizer; Roche
Speakers' Bureau - Abdi Ibrahim; Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Eczacibasi; Gen Ilaç; Janssen; Merck Serono; MSD; Novartis; Pfizer; Roche
Travel, Accommodations, Expenses - Abdi Ibrahim; Bristol-Myers Squibb; Eczacibasi; Gen Ilaç; Pfizer; Roche
 
Elena Verzoni
Honoraria - Eisai; Ipsen; Janssen; MSD Oncology; Novartis
Consulting or Advisory Role - Janssen Oncology; MSD/AstraZeneca; Pfizer
 
Juan Carlos Vázquez Limón
Honoraria - AstraZeneca; Bristol-Myers Squibb; MSD
Consulting or Advisory Role - AstraZeneca; Janssen; Roche
Research Funding - Abbvie; Amgen; AstraZeneca; Bristol-Myers Squibb; Celltrion; Daiichi Sankyo/Astra Zeneca; Exelixis; GlaxoSmithKline; Immunocore; Janssen; Mabxience; Mirati Therapeutics; MSD; Novartis; Olema Pharmaceuticals; Pfizer; Regeneron; Roche; Samsung Bioepis; Sandoz; Sanofi; Summit Therapeutics; Taiho Oncology
Travel, Accommodations, Expenses - Bristol-Myers Squibb (Mexico); Bristol-Myers Squibb (Mexico); GlaxoSmithKline; GlaxoSmithKline; Immunocore; Janssen; Janssen; Janssen; MSD; MSD; Roche; Summit Therapeutics; Summit Therapeutics; Summit Therapeutics
(OPTIONAL) Uncompensated Relationships - MSD; Roche; Roche; Roche
 
Camillo Porta
Consulting or Advisory Role - Angelini Pharma; AstraZeneca; Bristol-Myers Squibb; Eisai; Exelixis; Genenta Science; Genmab; Ipsen; Merck Serono; MSD
Speakers' Bureau - Angelini Pharma; Eisai; Ipsen; MSD
Research Funding - Merck Serono (Inst)
Travel, Accommodations, Expenses - Ipsen; MSD
Other Relationship - Genenta Science; MSD
(OPTIONAL) Uncompensated Relationships - AtG; Biorek; Medendi
 
Hong Liu
Employment - Merck
Stock and Other Ownership Interests - Merck
 
Manish Sharma
Employment - Merck
Stock and Other Ownership Interests - Merck; Regeneron
 
Joseph Burgents
Employment - Merck
Stock and Other Ownership Interests - Merck; Merck (I)
 
Thomas Powles
Honoraria - Astellas Pharma; AstraZeneca; BMS GmbH & Co. KG; Eisai; Exelixis; Incyte; Ipsen; Johnson & Johnson/Janssen; MashupMD; Merck; Merck Serono; Novartis; Pfizer; Roche; Seagen
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Eisai; Exelixis; Incyte; Ipsen; Johnson & Johnson; MashupMD; Merck; Merck Serono; MSD; Novartis; Pfizer; Roche; Seagen
Research Funding - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Eisai; Exelixis; Ipsen; Johnson & Johnson; Merck Serono; MSD; Novartis; Pfizer; Roche; Seagen
Travel, Accommodations, Expenses - AstraZeneca; Ipsen; MSD; Pfizer; Roche